{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-101447","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.613015+00:00","generated_at":"2026-05-17T02:55:23.390858+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial","bullets":["Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.","Zero non-response/relapse in AP-SA02 arm at one week post-BAT and EOS vs ~25% placebo (p<0.025).","AP-SA02 well-tolerated; no serious adverse events related to study drug; TEAEs 6% AP-SA02 vs 0% placebo.","Armata plans to initiate a pivotal Phase 3 superiority trial in 2026, subject to FDA feedback.","Defined phage variants in AP-SA02 show intrinsic adaptive mechanism to patient isolates, may enhance efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-101447","json":"https://secwatch.observer/filing/0001104659-25-101447.json","markdown":"https://secwatch.observer/filing/0001104659-25-101447.md","text":"https://secwatch.observer/filing/0001104659-25-101447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/0001104659-25-101447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/tm2529060d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:55:23.390858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}